With current radiotherapy to treat prostate cancer, there is no chance of knowing where the tumour is while treatment is being given. A considerably larger prostate area is irradiated as a result, risking side-effects that will reduce quality of life.

RayPilot® can be compared with a GPS system which allows the position of the organ in relation to the radiation to be monitored constantly, and the purpose of this is to make it possible to reduce damage to the surrounding tissue while at the same time being able to administer a more appropriate dose of radiation in order to kill off the cancerous tumour.

Recently published results from Sahlgrenska University Hospital in Gothenburg show that the prostate can move by more than 1 cm during radiotherapy and that this movement is entirely unpredictable. There is currently no system other than RayPilot® installed in the Nordic region which can constantly detect this movement during treatment.

The publication also describes the fact that the prostate can move in different ways, from moving very quickly and suddenly to considerably slower movement, and in the publication the team of researchers concludes that continuous monitoring of this movement significantly improves the chances of providing good treatment.

RayPilot® is currently installed for use in prostate cancer therapy in Sweden, Denmark, Germany and Italy, but the technology is also intended for use in radiotherapy for breast cancer, gynaecological cancer, cancer of the liver and childhood cancer, all of which are forms of cancer where there is currently a great risk of mobility during treatment.

For more information contact:
Tomas Gustafsson, CEO as Micropos Medical AB (publ), +46 (0) 31 772 80 99

www.micropos.se